In a controlled study comprising 176 patients, quinidine in the form of Kinidin Durules was found to reduce significantly the recurrence of atrial fibrillation during a I-year follow-up period after successful electric shock conversion. After one year, _5i per cent (52/iOI) of the patients in the quinidine group, and 28 per cent (2I/75) in the control group remained in sinus rhythm (P< o.OOi). No less than 43 per cent of the patients converted to sinus rhythm during treatment with maintenance doses of quinidine sulphate before intended DC conversion. Gastrointestinal side-effects were not uncommon, and caused interruption ofquinidine treatment in some cases.
The introduction of electric shock conversion to sinus rhythm, little more than a decade ago (Lown, Amarasingham, and Neuman, I962) , provided an effective method of treating various arrhythmias. In the majority of countries, electric conversion has replaced quinidine conversion of atrial fibrillation since the former is more effective and less hazardous.
The outstanding problem is how to prevent recurrence of fibrillation after conversion. Among various drugs which have been used for this purpose, quinidine has gained the widest acceptance. The value of quinidine is, however, a subject of controversy. Korsgren et al. (i965) , Rossi and Lown (i967) , and Cramer (1968) found quinidine to be effective while, for example, Oram and Davies (I964), Halmos (i966), Hall and Wood (i968) , Gunning et al. (1970) , and Waris, Kreus, and Salokannel (I97I) decided it was not. Some authors also consider that the risks of quinidine treatment are so great that it is doubtful whether quinidine should be used prophylactically to prevent a recurrence of arrhythmia after conversion (Oram and Davies, I964; Radford and Evans, I968; Aberg, I969) .
With the exception of two investigations published since the beginning of the present study (Hartel et al., I970; Hillestad et al., I97I) , the majority of previous investigations have comprised a Received 4 December I974.
limited number of patients, have lacked suitable control groups, and have involved the use of rapidly disintegrating quinidine tablets. Pharmacokinetic studies suggest that in order to maintain adequate and constant concentrations of quinidine in the blood, quinidine should be administered in the form of sustained release tablets (Cramer, Varnauskas, and Werk6, I963; Torok et al., I970) .
In view of this background, a controlled investigation was started in I969 to I970 in order to establish the value of quinidine for the maintenance of sinus rhythm after conversion of atrial fibrillation. In order also to investigate whether treatment with quinidine influences the result of DC conversion, the patients were randomly allocated to a quinidine group or an untreated control group before conversion.
By performing the investigation in the form of a multicentre study, with several Stockholm hospitals participating, it was possible to obtain a sufficiently large number of patients within a reasonable period of time. between the hospitals, and anticoagulants were given for at least three weeks before admission to hospital in 40 per cent of the patients. The patients underwent follow-up outpatient examinations with electrocardiographic control after I, 3, 6, and I2 months if sinus rhythm persisted or until recurrence of atrial fibrillation was recorded at the check-up. In the event of side-effects being so severe that the patient had to discontinue treatment with quinidine or reduce the dose by more than 0.4 g per day, the patient dropped out of the study. A thorough history concerning side-effects was also taken at these visits.
Subjects and methods
The fate of the few patients not coming to the outpatient clinics for check-ups was investigated by contact with appropriate parish office, where in Sweden a register of births, deaths, and other personal data is kept.
Within the framework of the large investigation a small crossover study on patients in the control group who suffered recurrence of fibrillation during the follow-up period was also performed. These patients were readmitted to hospital, converted once again, and now placed on prophylactic quinidine therapy. The patients were submitted to control examinations after i, 3, 6, and I2 months.
Results I) Initial quinidine treatment in hospital During initial treatment with quinidine in hospital 9I patients (43%) converted to sinus rhythm. One of these patients died suddenly.' In a further 8 patients quinidine treatment was discontinued because of syncope (i patient), ventricular ectopic beats with bigeminy (I patient), and diarrhoea (6 patients). Of these 6 patients, 4 also had pyrexia.
Two patients suffered early recurrence of atrial fibrillation during their stay in hospital, and were, therefore, excluded from the study.
Eighty patients in sinus rhythm proceeded to the follow-up outpatient phase of the study.
1A 70-year-old woman, with a history of hospital treatment of chest pain one year previously, was on diuretics and methyldopa because of hypertension. After a fortnight's history of pyrexia and myalgia, for which she had been given tetracycline, she was admitted to hospital because of central chest pain. On admission she was in cardiac failure, and the rhythm was atrial fibrillation with rapid ventricular rate (120/min). The blood pressure was I80/Ioo mmHg (23.9/ 13.3 kPa). A chest x-ray revealed a few scattered opacities and slight cardiac enlargement. The electrocardiogram confirmed the arrhythmia and showed left anterior hemiblock. Enzyme series excluded acute myocardial infarction and the patient made a rapid recovery. The diagnosis was a viral infection, and conversion of her atrial fibrillation was decided upon. Two weeks after admission, quinidine therapy (see above) was started and on the following day she was in sinus rhythm and digitalis therapy was instituted. The patient was found dead in her bed the following moming.
Necropsy revealed moderate subendocardial fibrosis and only minimal signs of coronary artery disease. There were no signs of recent myocardial infarction or myocarditis. The distribution with respect to functional groups (Table 4) was largely similar in the quinidine and control groups. Nor was there any great difference between the groups as regards the duration of atrial arrhythmia before conversion (Table 5 ).
The same proportion of patients had been treated with digitalis or diuretics in the two groups. The relative heart volume in the quinidine group was 527 ± 86 (range 320-690) ml/m2, and in the control group 546 ± 94 (range 330-690) ml/m2.
Of the patients in the quinidine group, 24 per cent had previously been treated with DC conversion compared to I9 per cent in the control group. Fig. 2 shows the number of patients in the quinidine and control groups, respectively, who remained in sinus rhythm after I, 3, 6, and I2 months. At the 12-month examination there was a significant difference in favour of quinidine (Table 6 ). The difference still persists if patients who suffered a recurrence of atrial arrhythmia or who were excluded from the study during the follow-up period because of side-effects are added to the quinidine group.
4) Complications during follow-up period
Two patients in the control group died during the follow-up period, 4 and 5 months, respectively, after discharge from hospital in sinus rhythm. The causes of death were myocardial infarction and cerebral vascular lesions, respectively. Three patients dropped out during the follow-up but all were alive more than I2 months after discharge from hospital.
Five patients in the quinidine group died during the follow-up period. None of these deaths was ascribed to quinidine (Table 7) . Six patients in the quinidine group dropped out during the follow-up period but all were alive more than I2 months after discharge from hospital. A further 3 patients in the 
5) Other side-effects during follow-up period
Twelve patients (I2%) in the quinidine group interrupted treatment because of side-effects, usually diarrhoea. Side-effects were most frequent during the initial phase of the follow-up period. The quinidine dose was reduced by 0.4 g per day or less in 46 (46%) patients. Twenty-one of these reported diarrhoea, but in no less than 25 patients, the dose was reduced without medical indication.
6) Crossover study Of the 49 patients in the control group who suffered recurrence of atrial arrhythmia during the followup period, 33 were discharged from hospital on quinidine after renewed conversion. Five of these were excluded from the study before the first examination, one month after discharge. Two patients were excluded because of diarrhoea, one because of fever and urticaria, and one because of tinnitus: these symptoms were considered to be caused by treatment with quinidine. One patient was excluded from the study because of a reduction of the dose of quinidine by more than 0.4 g without medical indication.
On examination after one month, 22 remained in sinus rhythm. Atrial arrhythmia had recurred in 6. After three months, atrial arrhythmia had recurred in I further patient. There was no recurrence of arrhythmia between three and six months. One year after discharge from hospital, 17 of the 33 patients in the control group who had been treated with quinidine remained in sinus rhythm (Fig. 3) (I97I) . In the present investigation, the proportion of women was higher in the control group than in the group treated with quinidine; there is, however, no evidence in previous investigations that sex influences maintenance of sinus rhythm after DC conversion. As regards age, duration of arrhythmia, functional group, treatment of heart failure, and heart volume, there were no significant differences between the groups. Mitral valve disease was more common in the control group than in the quinidine group. Radford and Evans (I968) and Gunning et al. (1970) consider that this type of patient has a greater tendency to suffer recurrence of fibrillation, both with and without quinidine. In the present investigation, sinus rhythm persisted in only I2.5 per cent after one year in patients with mitral valve disease in the control group, irrespective of whether or not they had been operated upon, while 50 per cent of the patients in the quinidine group with mitral valve lesions remained in sinus rhythm after the same period of time. Quinidine was thus effective in preventing recurrence of fibrillation even in patients with mitral valve -fever + urticaria 1 pat -vertigo 1 pat = still in S. R.
-dose-reduction 1 pat (no medical reason) F I G. 3 Results from crossover study. Effect of quinidine on maintaining sinus rhythm after conversion of atrial fibrillation or flutter 49I disease, so that the overrepresentation of such patients in the control group did not influence the results of the study as a whole (Table 3) . Exclusion of this category of patients does not influence the statistically significant difference between the quinidine and control group. This investigation thus shows that treatment with quinidine reduces the recurrence of atrial arrhythmia after conversion to sinus rhythm. These results are in agreement with previous studies (Korsgren et Cramer (I968) showed that a duration of atrial fibrillation of less than 6 months increased the likelihood of successful conversion. In the present study, patients with a duration of atrial arrhythmia of three years or more were excluded and approximately 75 per cent of the patients had had their arrhythmias for less than 6 months before the attempt at conversion. These criteria for inclusion of the patients in the study, and also possible selection of patients before referral to the participating hospitals for conversion, mean that the material is selected.
The results seem to indicate that the administration of quinidine before electroconversion had no effect on the success rate of conversion. This is in agreement with the results published by Hillestad, Dale, and Storstein (I972) and by Szekely et al.
(I97oa).
One patient treated with maintenance doses of quinidine in the present study died before being discharged from hospital. A not inconsiderable incidence of sudden deaths in patients with atrial fibrillation has been reported even without quinidine treatment (Cramer, I968; Takkunen et (Cramer, I968) , and can probably also occur when moderate maintenance doses of quinidine are given. However, it seems to be rare, and it is doubtful whether treatment with quinidine is significantly more hazardous than with many other antiarrhythmic agents in widespread use.
In the present study, a slow release form of quinidine was used. Despite administration of only two doses daily, a constant blood concentration of quinidine without high peaks was achieved. This is in agreement with previous reports (Cramer et Crossover studies supporting the value of treatment with quinidine for prevention of recurrence of fibrillation after electric cardioversion have been performed by, for example, Resnekov et al. (I97I) . In the present study a nonsystematic crossover experiment was performed with 33 of the 49 patients from the control group in whom atrial fibrillation had recurred (Fig. 3) . They were converted to sinus rhythm once more, but this time they left the hospital with prophylactic quinidine treatment. During the first month five were excluded from the study, two because of diarrhoea, one because of fever, one because of vertigo, and one because of a dosage reduction of more than 0.4 g without medical reason. Atrial fibrillation had recurred in six patients, while 22 were still in sinus rhythm. One year after discharge, I7 of the 33 patients in the control group who had been treated with quinidine remained in sinus rhythm. 
